Research

Hormonal

Tirzepatide produces significantly greater monthly and annual weight loss, higher patient satisfaction, and improved quality of life compared to Semaglutide and Liraglutide in a Kuwaiti population.

If you are considering GLP-1 therapy for weight loss in Kuwait, Tirzepatide appears to offer the highest weight loss and satisfaction rates compared to Semaglutide and Liraglutide. Be aware that side effects like belching (Tirzepatide) or anxiety (Liraglutide) may influence your choice, and check government facility availability to manage costs.

ModerateSupportsMEDIUM confidence
Tirzepatide users (N = 132; 27.8%) reported significantly higher monthly and annual weight-loss (4.76 ± 2.82 kg/month; 8.48 ± 4.04 kg/year), and greater satisfaction (88%) and improved quality of life (60%) compared to both Semaglutide (N = 181; 37.2%) and Liraglutide (N = 152; 31.3%), respectively.
Saad Al‐Ali et al. · Frontiers in Nutrition · 2025

Why this rating

Cross-sectional survey design with self-reported data introduces recall bias and lacks controlled dosing verification, though the sample size is large.

Source

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait

Saad Al‐Ali et al. · Frontiers in Nutrition · 2025

DOI 10.3389/fnut.2025.1590379

cross_sectional · n=486Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →